Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Pathology Oncology Research : POR
|
October 10, 2022
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
Ferenc Takács, Lili Kotmayer, Ágnes Czeti, et al.
Journal of the National Cancer Institute
|
October 5, 2006
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial
Andrés J M Ferreri, Maurilio Ponzoni, Massimo Guidoboni, et al.
Leukemia & Lymphoma
|
October 10, 2025
Expert consensus opinion on the management of hairy cell leukemia in elderly patients
Tamar Tadmor, Judit Demeter, Andrei Fagarasanu, et al.
British Journal of Haematology
|
August 14, 2008
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma
Andrés J M Ferreri, Giuseppina P Dognini, Osnat Bairey, et al.
The Lancet. Haematology
|
March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2017
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo, Marek Trněný, David Belada, et al.
American Journal of Hematology
|
December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Journal of Internal Medicine
|
June 1, 2023
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
Ákos Nagy, Bence Bátai, Laura Kiss, et al.
Leukemia Research
|
January 7, 2018
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms
Ambrus Gángó, Réka Mózes, Zsófia Boha, et al.
International Journal of Molecular Sciences
|
March 29, 2023
Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
Lili Kotmayer, Tamás László, Gábor Mikala, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Pathology Oncology Research : POR
|
October 10, 2022
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
Ferenc Takács, Lili Kotmayer, Ágnes Czeti, et al.
Journal of the National Cancer Institute
|
October 5, 2006
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial
Andrés J M Ferreri, Maurilio Ponzoni, Massimo Guidoboni, et al.
Leukemia & Lymphoma
|
October 10, 2025
Expert consensus opinion on the management of hairy cell leukemia in elderly patients
Tamar Tadmor, Judit Demeter, Andrei Fagarasanu, et al.
British Journal of Haematology
|
August 14, 2008
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma
Andrés J M Ferreri, Giuseppina P Dognini, Osnat Bairey, et al.
The Lancet. Haematology
|
March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2017
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo, Marek Trněný, David Belada, et al.
American Journal of Hematology
|
December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Journal of Internal Medicine
|
June 1, 2023
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma
Ákos Nagy, Bence Bátai, Laura Kiss, et al.
Leukemia Research
|
January 7, 2018
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms
Ambrus Gángó, Réka Mózes, Zsófia Boha, et al.
International Journal of Molecular Sciences
|
March 29, 2023
Landscape of <i>BCL2</i> Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
Lili Kotmayer, Tamás László, Gábor Mikala, et al.
Page
of 9